Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEB071 plus everolimus in relapsed diffuse large B-cell lymphoma
NL-OMON40516Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sotrastaurin and everolimus in diffuse large B-cell lymphoma (DLBCL) and non-Hodgkin lymphoma (NHL), sponsored by Novartis. Primary endpoints: Maximum tolerated dose, Recommended Phase II dose and 1 more. Started Jun 2014; status: active, not recruiting.
02
Drugs
sotrastaurineverolimus
03
Conditions
diffuse large B-cell lymphoma (DLBCL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NL-OMON40516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40516.